CorMedix initiated with a Buy at Roth Capital. Roth Capital analyst Jerry Isaacson started coverage of CorMedix with a Buy rating and $6 price target. The analyst notes that the company is developing Neutrolin for the prevention of catheter-related blood stream infections in patients with central venous catheters, and believes there is a large market opportunity for Neutrolin in multiple patient populations. CorMedix has Fast-Track designation from the FDA and QIDP designation, leading to 10.5 years of market exclusivity, he adds.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.